Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Drug: HUYPS-1 nine tabletsDrug: HUYPS-1 one tablet
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05983328
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Management
Phase 2
- Conditions
- Pain, Postoperative
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05842733
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Beitou District, Taiwan
A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers
Not Applicable
Recruiting
- Conditions
- HepatitisPharmacology
- Interventions
- Drug: SafeTynadol®
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05563961
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei City, Neihu District, Taiwan
To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05557448
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Beitou District, Taiwan
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04808154
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD
Phase 2
Terminated
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: SNP-612 dose1Drug: SNP-612 dose2
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT03868566
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
Phase 2
Not yet recruiting
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03468556
A Randomized, Single-blind, Parallel Group and Multiple - Dose Design Study
Not Applicable
Completed
- Conditions
- Acetaminophen Toxicity
- Interventions
- Drug: SafeTynadol®
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03451487
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Neihu District, Taiwan
© Copyright 2025. All Rights Reserved by MedPath